降钙素原通过降钙素基因相关肽受体在脓毒性休克中发挥介质作用
该研究为前瞻性随机动物实验及人血体外研究,使用降钙素原缺陷小鼠在盲肠结扎穿孔和內毒素血症模型中探究降钙素原的介质作用及受体。结果显示降钙素原缺陷小鼠免于脓毒性休克且肺部炎症减轻;降钙素原通过 innate 免疫细胞促进IL-17A表达,并与创伤后脓毒症患者全身IL-17A水平正相关。CGRP受体拮抗剂olcegepant抑制降钙素原信号并延长脓毒性休克小鼠生存时间,提示CGRP受体抑制剂在脓毒症中的潜在治疗价值,但需进一步临床研究。
要点
- 降钙素原缺陷小鼠在盲肠结扎穿孔和內毒素血症模型中免于脓毒性休克,且肺部炎症减轻。
- 降钙素原促进先天免疫细胞促炎细胞因子表达,为γδ T细胞表达IL-17A所必需;创伤后脓毒症患者降钙素原与全身IL-17A水平正相关。
- 內毒素血症小鼠中免疫中和IL-17A可抑制降钙素原对疾病结局的有害效应。
- 降钙素受体表达与疾病进展无关;非肽类CGRP受体拮抗剂olcegepant抑制降钙素原信号并延长脓毒性休克小鼠生存时间。
- 实验数据提示降钙素原对实验性脓毒性休克疾病进展有中度但有害的作用,CGRP受体抑制剂在脓毒症的潜在治疗应用尚需进一步临床研究。
适用人群与场景
- C57BL/6J小鼠(降钙素原缺陷小鼠及对照)用于实验性脓毒性休克研究。
- 创伤后脓毒症患者血清样本用于验证主要发现。
- 体外培养的巨噬细胞、树突状细胞和γδ T细胞用于机制研究。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性随机动物实验及人血体外研究;样本量与中心数原文未提及。
- 人群:C57BL/6J小鼠及创伤后脓毒症患者;干预:降钙素原缺陷小鼠、盲肠结扎穿孔和內毒素血症模型、olcegepant;对照:原文未明确描述对照设置。
- 关键次要终点:降钙素原促进先天免疫细胞促炎细胞因子表达,为γδ T细胞IL-17A表达所必需;创伤后脓毒症患者降钙素原与全身IL-17A水平正相关;內毒素血症小鼠中免疫中和IL-17A抑制降钙素原的有害效应;olcegepant抑制降钙素原信号并延长生存时间;原文未提供具体数值。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:前瞻性随机动物实验及人血体外研究(非RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:实验数据提示降钙素原对实验性脓毒性休克有中度但有害的作用;CGRP受体抑制剂在脓毒症的潜在治疗应用尚需进一步临床研究。
对床旁实践的改变
- 原文提示降钙素原在实验性脓毒性休克中经CGRP受体发挥有害介质作用,但尚不能改变临床常规使用降钙素原作为生物标志物的做法。
- olcegepant为CGRP受体拮抗剂,在脓毒性休克小鼠中延长生存时间,但尚未在患者中验证,不能用于临床脓毒症治疗。
- 适用与不适用人群:原文未明确界定临床适用人群;需注意动物实验与人体间的转化差距。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Clinically, procalcitonin represents the most widely used biomarker of sepsis worldwide with unclear pathophysiologic significance to date. Pharmacologically, procalcitonin was shown to signal through both calcitonin receptor and calcitonin gene-related peptide receptor in vitro, yet the identity of its biologically relevant receptor remains unknown.
DESIGN: Prospective randomized animal investigations and in vitro human blood studies.
SETTING: Research laboratory of a university hospital.
SUBJECTS: C57BL/6J mice and patients with post-traumatic sepsis.
INTERVENTIONS: Procalcitonin-deficient mice were used to decipher a potential mediator role in experimental septic shock and identify the relevant receptor for procalcitonin. Cecal ligation and puncture and endotoxemia models were employed to investigate septic shock. Disease progression was evaluated through survival analysis, histology, proteome profiling, gene expression, and flow cytometry. Mechanistic studies were performed with cultured macrophages, dendritic cells, and gamma delta T cells. Main findings were confirmed in serum samples of patients with post-traumatic sepsis.
MEASUREMENTS AND MAIN RESULTS: Procalcitonin-deficient mice are protected from septic shock and show decreased pulmonary inflammation. Mechanistically, procalcitonin potentiates proinflammatory cytokine expression in innate immune cells, required for interleukin-17A expression in gamma delta T cells. In patients with post-traumatic sepsis, procalcitonin positively correlates with systemic interleukin-17A levels. In mice with endotoxemia, immunoneutralization of interleukin-17A inhibits the deleterious effect of procalcitonin on disease outcome. Although calcitonin receptor expression is irrelevant for disease progression, the nonpeptide calcitonin gene-related peptide receptor antagonist olcegepant, a prototype of currently introduced antimigraine drugs, inhibits procalcitonin signaling and increases survival time in septic shock.
CONCLUSIONS: Our experimental data suggest that procalcitonin exerts a moderate but harmful effect on disease progression in experimental septic shock. In addition, the study points towards the calcitonin gene-related peptide receptor as relevant for procalcitonin signaling and suggests a potential therapeutic application for calcitonin gene-related peptide receptor inhibitors in sepsis, which warrants further clinical investigation.
参考来源
- Baranowsky A, Appelt J, Kleber C, et al. Procalcitonin Exerts a Mediator Role in Septic Shock Through the Calcitonin Gene-Related Peptide Receptor. Crit Care Med. 2021. PMID: 33196529. doi:10.1097/CCM.0000000000004731
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。